Navigation Links
Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
Date:10/23/2013

MILLBROOK, N.Y., Oct. 23, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc. is pleased to announce the appointment of Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee.

Dr. Fury is a Medical Oncologist in The Department of Medicine at Memorial Sloan-Kettering. Since 2006 Dr. Fury has been conducting clinical research focused on mTOR/eIF4E inhibitors for Human Papilloma related head and neck cancers. He will now be participating in a collaboration with Egenix in the development of a drug for HPV.

We at Egenix are delighted to have Dr. Fury aboard.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers, autism, and Alzheimer's. Our lead drug candidates inhibit the "translation initiation factor" eIF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated be a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.


'/>"/>
SOURCE Egenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Egenix, Inc. Announces New Director, John Reid
2. Egenix, Inc. Announces New Director
3. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
4. ACTUS Appoints New Members to Its Management Team
5. Immune Design Appoints Stephen R. Brady Chief Business Officer
6. DiaVacs, Inc. Appoints Orville Kolterman, M.D. As Chief Medical Officer
7. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
8. Solulink Appoints Life Science Industry Veteran Jack Ball as Chief Executive Officer
9. Cold Spring Harbor Laboratory Appoints Teri F. Willey to Accelerate Commercialization Efforts
10. Senn Chemicals Appoints New Chief Executive Officer
11. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the ... around the world, is pleased to announce the 2nd annual Precision Medicine Virtual ... premier, online-only conference focused on the development and advancements in precision medicine. , ...
(Date:2/22/2017)... VIRGINIA (PRWEB) , ... February 22, 2017 , ... ... today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the ... CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert Consultant. ...
(Date:2/21/2017)... TORONTO , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ... financial and operational results for the three months ended December ... Toronto -based life sciences and diagnostics company that develops ... ... "We continue to build on the commercial milestones achieved in ...
(Date:2/21/2017)... ... 2017 , ... The medical potential of stem cells is both extensive and ... due to their differentiating characteristics. Stem cells are unique as the have the potential ... to become tissue or organic-specific cells with special functions. , Stem cell therapy ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/10/2017)... , Feb 10, 2017 ... new report "Personalized Medicine - Scientific and Commercial Aspects" ... ... personalized medicine. Diagnosis is integrated with therapy for selection of ... on early detection and prevention of disease in modern medicine. ...
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
Breaking Biology News(10 mins):